预防高危早产儿支气管肺发育不良的新方法-猫眼课题宝

预防高危早产儿支气管肺发育不良的新方法

批准号：

10765750

负责人：

Suchismita Acharya

金额：

$20.4万

依托单位：

AYUVIS RESEARCH, INC.

依托单位国家：

美国

项目类别：

财政年份：

2023

资助国家：

美国

项目状态：

已结题

起止时间：

2023-06-01 至 2024-04-30

来源：

https://reporter.nih.gov/project-details/10765750

关键词：

Adolescent Adrenal Cortex Hormones Adult Affect Agreement Alveolar Angiogenic Factor Animals Anti-Inflammatory Agents Antiinflammatory Effect Bacteremia Binding Bolus Infusion Brain Bronchopulmonary Dysplasia Canis familiaris Cardiac Cardiotoxicity Cell Death Cells Cessation of life Childhood Chitin Clinic Clinical Clinical Trials Complication Data Development Diagnosis Disease Dose Dysplasia Enzyme-Linked Immunosorbent Assay Exposure to Gases Genetic Predisposition to Disease Gestational Age Glucosamine Goals Gram-Negative Bacteria Gram-Negative Bacterial Infections Grant Growth Factor Human Hyperoxia Immune response Immunity Immunologist Impairment In Vitro Incidence Infant Infection Inflammation Inflammation Mediators Inflammatory Injections Injury Interleukin-1 beta Interleukin-10 Interleukin-6 Intraperitoneal Injections Investigational New Drug Application Lead Life Lung Lymphocyte Macrophage Measures Mechanical Ventilators Mechanical ventilation Modeling Molecular Weight Mus Neonatal Neonatal Intensive Care Units Newborn Infant No-Observed-Adverse-Effect Level Oligosaccharides Orphan Outcome Measure Oxygen Pathologic Pathway interactions Phagocytosis Pharmaceutical Preparations Phenotype Physiology Plasma Play Premature Birth Premature Infant Prevention Prevention approach Production Prophylactic treatment Proteins Pulmonary Hypertension Pulmonary Inflammation Rattus Recovery Regimen Reporting Research Respiratory Disease Respiratory Failure Rest Risk Role Safety Scientist Secondary to Series Serine Serum Signal Transduction TLR4 gene TNF gene Techniques Testing Threonine Time Toxicokinetics Transforming Growth Factor beta Treatment Efficacy Umbilical Cord Blood Universities Up-Regulation Utah Uterus Vascular Endothelial Growth Factors Vascularization Ventilator Work antagonist antenatal chronic respiratory disease comorbidity cytokine cytotoxicity drug development early childhood efficacy testing endothelial dysfunction genotoxicity human model immunoregulation improved in vitro testing intravenous injection lamb model lead candidate lung injury manufacture meetings monocyte mouse model neonatal mice neonate neurotensin mimic 1 novel novel strategies novel therapeutics peripheral blood pre-Investigational New Drug meeting prenatal preterm newborn prevent programs prophylactic pulmonary function pup respiratory small molecule surfactant tissue repair vasculogenesis ventilation

中文摘要

翻译

摘要支气管肺发育不良(BPD)是婴儿最常见的慢性呼吸道疾病，是一种继发于早产的一种破坏肺部发育程序的破坏性状况。Bpd 影响暴露在机械通风下的新生儿，到目前为止，还没有特定的药物可用于预防或者治疗这种危及生命的疾病。BPD的病理特征是高氧性肺损伤。炎症，细胞死亡增加，调节失调的血管生成因子最终导致肺泡化受损，肺血管形成失调和肺高压。AyuVis研究公司正在开发一种新型低分子天然低聚糖小分子激活巨噬细胞通过TLR4信号转导到非炎症性表型。我们的主要候选AVR-48与TLR4绑定，从而靶细胞选择性激活阻断肺内炎性介质及上调内源性激素血管形成途径改善肺血管形成，从而改善肺功能。AVR-48有一个氨基葡萄糖核心，使其对肺蛋白的丝氨酸/苏氨酸的O-GlcN酰化反应，一个保守的对损伤的防御，使细胞重塑。此外，它还能提高某些寄主抗病原的产量。 IL-10和生长因子血管内皮生长因子等炎症分子对血管形成的影响仍局限于肺部。我们已经证明，腹膜腔内注射AVR-48可以预防高氧诱导的BPD。 10 mg/kg剂量和静脉注射有创机械呼吸机诱导的新生小鼠幼鼠模型早产羔羊BPD剂量为0.3 mg/kg-3.0 mg/kg。为了推进领先的候选AVR-48，AyuVis 提出三个相辅相成的目标：(1)确定早产羔羊模型的安全性和长期疗效测试AVR-48预防性治疗是否能改善长期呼吸、心脏和心脏功能在出生2个月后测量神经发育结果，以模拟婴儿1-2年的生活；(2)展示用细胞毒实验检测AVR-48对高氧攻击后人脐血的抗炎作用炎症和抗炎介质和巨噬细胞；以及(3)测定毒代动力学参数。幼年大鼠，将被用来在临床上模拟人的等量剂量。这些研究有望提供机械和确凿的功效数据，使AVR-48能够进入GMP生产和提交一份研究用新药申请。

英文摘要

ABSTRACT Bronchopulmonary Dysplasia (BPD) is the most common chronic respiratory disease in infants and is a devastating condition that disrupts the developmental program of the lung secondary to preterm birth. BPD affects neonates exposed to mechanical ventilation and, to date, there are no specific drugs available to prevent or treat this life-threatening condition. The pathologic hallmarks of BPD are hyperoxia-induced pulmonary inflammation, increased cell death, dysregulated angiogenic factors culminating in impaired alveolarization, dysregulated vascularization of the lung and pulmonary hypertension. AyuVis Research, Inc, is developing a novel class of low molecular weight natural oligosaccharide-derived small molecules which activate macrophage to a non-inflammatory phenotype via TLR4 signalling. Our lead candidate AVR-48 binds to TLR4 resulting in selective activation of the target cell to block inflammatory mediators in lung and upregulation of endogenous vascularization pathways improving lung vascularization leading to improved lung function. AVR-48 has a glucosamine core, making it responsive to O-GlcNAcylation of serine/threonine of lung proteins, a conserved defense against injury that enables cellular remodeling. Additionaly, it enhances production of certain host anti- inflammatory molecule such as IL-10 and growth factor VEGF with vascularization effects remaining local to lungs. We have demonstrated that intraperitoneal injection of AVR-48 prevents hyperoxia-induced BPD in a neonatal mice pup model at 10mg/kg dose and intravenous injection in invasive mechanical ventilator induced BPD in pre-term lambs at 0.3mg/kg-3.0 mg/kg doses. In order to advance the lead candidate AVR-48, AyuVis is proposing three complimentary aims: (1) Determine safety and long-term efficacy in the preterm lamb model by testing whether prophylactic treatment with AVR-48 improves the long-term respiratory, cardiac and neurodevelopmental outcomes measured after 2 months of life to mimic 1-2 years of infant life; (2) Demonstrate anti-inflammatory effect of AVR-48 in human cord blood after hyperoxia challenge by measuring cytotoxicity, inflammatory and anti-inflammatory mediators and macrophages; and (3) Determine toxicokinetic parameters in juvenile rats that will be used to model human equivalent dose in clinic. These studies are expected to provide mechanistic and confirmatory efficacy data which would enable AVR-48 to progress to GMP manufacturing and file an Investigational New Drug application.

期刊论文(0)

专著(0)

科研奖励(0)

会议论文